Natalizumab (Tysabri) Re-Initiation of Dosing

NCT00297232 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1094

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: Natalizumab

Sponsor

Biogen